GFM
AMLX icon

GF Fund Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

GF Fund Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.1K Buy
2,455
+297
+14% +$4.18K ﹤0.01% 445
2025
Q4 		$26.1K Buy
2,158
+240
+13% +$3.26K ﹤0.01% 478
2025
Q3 		$26.1K Buy
1,918
+218
+13% +$2.05K ﹤0.01% 460
2025
Q2 		$10.9K Hold
1,700
– – ﹤0.01% 562
2025
Q1 		$6.02K Buy
1,700
+261
+18% +$929 ﹤0.01% 612
2024
Q4 		$5.44K Buy
+1,439
New +$6.77K ﹤0.01% 607

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

GF Fund Management's AMLX Position: Q1 2026 in Review

GF Fund Management increased its Amylyx Pharmaceuticals (AMLX) stake by 14% in Q1 2026, buying an estimated $4.18K and bringing the position to 2,455 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #445.

GF Fund Management first reported a position in AMLX in Q4 2024 and has held it in 6 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • GF Fund Management held 2,455 shares of Amylyx Pharmaceuticals worth $34.1K as of Q1 2026.
  • GF Fund Management bought 297 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $4.18K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #445 holding.
  • GF Fund Management first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.